Neurocloud PET


Neurocloud PET for quantitative brain PET image analysis provides neurology and nuclear medicine professionals with automatic assistance in the diagnosis and monitoring of neurodegenerative diseases.
- FDG PET imaging: identifies regions with abnormal metabolism by comparative analysis against an extensive database of normals, stratified by age. An analysis based on regions of interest, asymmetries and parametric statistical analysis (voxel by voxel) is performed.
- Amyloid PET imaging: provides SUVR values and outcome (amyloid positive/negative) compared to validated thresholds.
Product specifications Information source: Vendor
Last updated: Dec. 6, 2021
Product name Neurocloud PET
Company Qubiotech
Subspeciality Neuro
Modality MR, PET
Disease targeted Alzheimer's Disease (AD), Parkinson, Dementia, Epilepsy, Encephalitis
Key-features Identify and quantify regions with abnormal metabolism, positive/negative amyloid result, customizable report
Suggested use During: perception aid (prompting all abnormalities/results/heatmaps), During: interactive decision support (shows abnormalities/results only on demand), During: report suggestion
Data characteristics
Population Patients from 9 to 89 yo
Input 18F-FDG 3D iterative reconstruction (mandatory), florbetaben, flutemetamol, flobetapiR, MRI T1 3D (optional)
Input format DICOM
Output Color image overlay, ROI analysis, asymmetries, parametric statistical analysis (voxel by voxel), SUVR calculation, positive/negative amyloid result, automatic quantification customizable report
Output format PDF, DICOM, NIFTI, EXCEL
Integration Integration in standard reading environment (PACS), Integration RIS (Radiological Information System), Integration via AI marketplace or distribution platform, Stand-alone third party application, Stand-alone webbased
Deployment Locally virtualized (virtual machine, docker), Cloud-based
Trigger for analysis On demand, triggered by a user through e.g. a button click, image upload, etc.
Processing time 1 - 10 minutes
Certified, Class I , MDD
No or not yet
Market presence
On market since 09-2017
Distribution channels Eureka Clinical AI, Alma HEALTH PLATFORM
Countries present (clinical, non-research use) 3
Paying clinical customers (institutes)
Research/test users (institutes)
Pricing model Pay-per-use, Subscription, Customizable Plans
Based on Number of installations, Number of analyses, Customizable Plans
Peer reviewed papers on performance

  • Simulated FDG-PET studies for the assessment of SUV quantification methods (read)

  • Iterative Structural and Functional Synergistic Resolution Recovery (iSFS-RR) Applied to PET-MR Images in Epilepsy (read)

  • Impact and correction of the bladder uptake on 18F-FCH PET quantification: A simulation study using the XCAT2 phantom (read)

  • Correction for FDG PET dose extravasations : Monte Carlo validation (read)

Non-peer reviewed papers on performance
Other relevant papers